Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Washington University School of Medicine
Georgetown University
Nektar Therapeutics
Nektar Therapeutics
Calithera Biosciences, Inc
Incyte Corporation
Duke University